辰光医疗
(430300)
| 流通市值：13.84亿 | | | 总市值：17.86亿 |
| 流通股本：6653.17万 | | | 总股本：8584.71万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 25,074,439.29 | 119,001,736.41 | 86,106,323.16 | 57,154,824.55 |
| 营业收入 | 25,074,439.29 | 119,001,736.41 | 86,106,323.16 | 57,154,824.55 |
| 二、营业总成本 | 36,275,290.39 | 165,878,663.16 | 115,412,560.94 | 76,954,002.08 |
| 营业成本 | 17,341,913.99 | 73,493,170.2 | 50,568,766.55 | 32,667,911.9 |
| 税金及附加 | 348,684.37 | 1,444,836.07 | 1,062,775.14 | 652,974.95 |
| 销售费用 | 5,468,888.85 | 29,630,249.91 | 23,137,000.76 | 15,857,078.76 |
| 管理费用 | 4,753,213.89 | 26,939,160.58 | 19,366,422.93 | 14,008,614.98 |
| 研发费用 | 7,231,154.86 | 29,438,979.69 | 17,729,835.43 | 11,515,845.64 |
| 财务费用 | 1,131,434.43 | 4,932,266.71 | 3,547,760.13 | 2,251,575.85 |
| 其中:利息费用 | 1,242,948.18 | 5,198,018.51 | 3,677,688.04 | 2,430,745.52 |
| 其中:利息收入 | 12,489.41 | 236,618.66 | 201,471.42 | 157,099.55 |
| 加:投资收益 | 19,239.45 | 695,523.34 | 389,185.83 | 272,736.48 |
| 资产处置收益 | - | -72,912.53 | -7,317.13 | -7,317.13 |
| 资产减值损失(新) | 827,510.68 | -22,098,174.01 | 407,054.03 | 527,859.98 |
| 信用减值损失(新) | 1,105,592.94 | -5,712,971.83 | 5,494,327.63 | 3,467,461.97 |
| 其他收益 | 841,982.45 | 5,315,518.08 | 2,868,011.89 | 1,453,970.85 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -8,406,525.58 | -68,749,943.7 | -20,154,975.53 | -14,084,465.38 |
| 加:营业外收入 | 52,969.8 | 143,439.06 | 158,439.06 | 155,438.99 |
| 减:营业外支出 | 19,000 | 57,470.3 | 256 | 307 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -8,372,555.78 | -68,663,974.94 | -19,996,792.47 | -13,929,333.39 |
| 减:所得税费用 | 210,146 | -7,765,339.44 | -4,121,455.63 | -2,722,282.16 |
| 六、净利润 | -8,582,701.78 | -60,898,635.5 | -15,875,336.84 | -11,207,051.23 |
| 持续经营净利润 | -8,582,701.78 | -60,898,635.5 | -15,875,336.84 | - |
| 归属于母公司股东的净利润 | -8,582,701.78 | -60,898,635.5 | -15,875,336.84 | -11,207,051.23 |
| (一)基本每股收益 | -0.1 | -0.71 | -0.18 | -0.13 |
| (二)稀释每股收益 | -0.1 | -0.71 | -0.18 | -0.13 |
| 九、综合收益总额 | -8,582,701.78 | -60,898,635.5 | -15,875,336.84 | -11,207,051.23 |
| 归属于母公司股东的综合收益总额 | -8,582,701.78 | -60,898,635.5 | -15,875,336.84 | -11,207,051.23 |
| 公告日期 | 2025-04-29 | 2025-04-25 | 2024-10-30 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |